FDA.reportPublic FDA data

tofacitinib 5 MG [Xeljanz]

RxCUI
1357543
RxNorm name
tofacitinib 5 MG [Xeljanz]
Term type
SBDC
Status
Active
Updated
2026-07-24 06:52:03

RxNorm Status History#

Status
Active
Source
RXNORM
Current
YES
Release start
122012
Active start
122012
Multiple ingredient
NO
Branded
YES

Ingredients And Strength#

Ingredient, Strength, Base table
IngredientStrengthBaseBasis of strength
5 MG / 1 EACHtofacitinib

Derived Ingredient Concepts#

Ingredient, RxCUI table
IngredientRxCUI
tofacitinib1357536

Source Vocabulary Codes#

Code type, Value, Category table
Code typeValueCategory
PRESCRIBABLEYATTRIBUTES
RXNAV_STRtofacitinib 5 MG [Xeljanz]NAMES
RxNorm Nametofacitinib 5 MG [Xeljanz]NAMES
TTYSBDCATTRIBUTES
RxCUI1357543CODES

Drug Classes#

Source, Class ID, Class table
SourceClass IDClassTypeRelationshipDrug concept
ATCL04AFJanus-associated kinase (JAK) inhibitorsATC1-4tofacitinib
FDASPLN0000190858Janus Kinase InhibitorEPChas_epctofacitinib
FDASPLN0000190857Janus Kinase InhibitorsMOAhas_moatofacitinib
MEDRTD010880PiperidinesCHEMhas_ingredienttofacitinib
MEDRTD011743PyrimidinesCHEMhas_ingredienttofacitinib
MEDRTD001172Arthritis, RheumatoidDISEASEmay_treattofacitinib
MEDRTN0000190857Janus Kinase InhibitorsMOAhas_moatofacitinib
MEDRTN0000008656Decreased HematopoiesisPEhas_petofacitinib
MEDRTN0000175550Decreased Immunologic ActivityPEhas_petofacitinib

Properties#

Category, Property, Value table
CategoryPropertyValue
ATTRIBUTESGENERAL_CARDINALITYSINGLE
ATTRIBUTESPRESCRIBABLEY
ATTRIBUTESRXNAV_HUMAN_DRUGUS
ATTRIBUTESTTYSBDC
CODESRxCUI1357543
NAMESRXNAV_STRtofacitinib 5 MG [Xeljanz]
NAMESRxNorm Nametofacitinib 5 MG [Xeljanz]